page of Zlatko Dembic - Frontpage
cell-biology & microbiology)
Molecular Genetics Group
Department of Oral Biology
Faculty of Dentistry,
University of Oslo
Postal address >
Institutt for oral biologi (IOB),
University of Oslo,
Tel: + 47 228 40 330 /
Fax: + 47 228 40 302
As a scientist with a medical
background, it's natural that my research interests are placed at the crossroads
of medicine and biology. Since the earliest days of my lab career I was attracted
to molecular and cellular immunology. The more I learned, the more my interest
evolved toward studying ontogeny and phylogeny of the immune system. The reason
was simple: I wished to understand its function, and that is still my wish.
During the last twenty years of the past century I've worked on important issues
in immunology at the Max-Planck-Institute for Biology (Tübingen, Germany), the
Basel Institute for Immunology (Switzerland; CH) and the Hoffman-La Roche AG
(Basel, CH). We were the first to report the identification of genes underlying
T-cell specificity and recognition (mouse T-cell receptor, in '86). Likewise,
we led the research on molecular cloning of human cytokine receptors important
for the effector phase of immunity such as the interferon-gamma receptor (IFNGR1;
in '88) and the tumor necrosis factor receptor-2 (TNFR2; in '90). In 1995, I
moved to the Institute of Immunology at the University of Oslo, Norway. Since
then I broadened the scope of my research by working on T-cell development,
cancer immunobiology, immunogenetics and susceptibility to cancer and infectious
diseases. All of this would not have been possible without a substantial contribution
from my academic collaborators and colleagues in Norway and Croatia. Some of
these studies led me to propose a model about the workings of the immune system
called the "integrity" model in the mid-nineties. It stresses that
immunity is not only a defense system, but also a selector of potential symbionts
and commensals. So far, my publication list has over 80 scientific contributions.
Ten percent were published in top scientific journals (Nature and Cell) with
myself as a prominent author (in half of them). I tend to take these achievements
as evidence of the great fun and joy that basic research in immunology has given
me over the past years. They are also the source of an unending motivation to
study further what remains unknown - a progressively smaller part of human body.
Here are some representative
articles (check here for more):
- Dembic Z, Bannwarth W, von Boehmer H and Steinmetz M:
The gene encoding the T-cell receptor alpha-chain maps close to the Np-2 locus on mouse chromosome 14.
Nature 314, 271-273
- Snodgrass HR, Dembic Z, Steinmetz M, and von Boehmer H:
Expression of T-cell antigen receptor genes during fetal development in the thymus.
Nature 315, 232-233
- Dembic Z, Haas W, Weiss
S, McCubrey J, Kiefer H, von Boehmer H and Steinmetz M:
Transfer of specificity
by murine alpha- and beta-chain T-cell receptor genes.
Nature 320, 232-238
- Dembic Z, Haas W, Zamoyska
R, Parnes J, Steinmetz M and von Boehmer H:
Transfection of the
CD8 gene enhances T cell recognition.
326, 510-511 (1987).
- Uematsu Y, Ryser S, Dembic Z, Borgulya P,
Krimpenfort P, Berns A, von Boehmer H, and Steinmetz M:
In transgenic mice the introduced functional
T-cell receptor beta gene prevents expression of endogenous beta genes
Cell 52, 831-841
- Aguet M, Dembic Z and
and expression of human IFN-gamma receptor.
Cell 55, 273-276
- Vidovic D, Roglic M,
McKune K, Guerder S, Mackay C, and Dembic Z:
Qa-1 restricted recognition
of foreign antigen by a gamma/delta T cell hybridoma.
Nature 340, 646-650
- Dembic Z, Loetscher H, Gubler U, Pan Y-CE, Lahm, H-W, Gentz R,
Brockhaus M, and Lesslauer W:
Two human TNF receptors have similar extracellular but distinct
intracellular domain sequences.
Cytokine 2, 231-237
- Russell DM, Dembic Z, Morahan G, Miller JFAP,
Burki K, and Nemazee D:
Peripheral deletion of self-reactive B cells.
Nature 354, 308-311
- Dembic Z, Schenck K,
and Bogen B:
Dendritic cells purified
from myeloma are primed with tumor-specific antigen (idiotype) and activate
CD4+ T cells. Proc
Natl Acad Sci USA 97, 2697-2702 (2000).
- Dembic Z, Røttingen
J-A, Dellacasagrande J, Schenck K and Bogen B:
dendritic cells purified from myelomas activate tumor-specific T cells at
a single cell level.
Blood 97, 2808-14 (2001).
- Dembic Z:
On Recognizing 'Shades-Of-Gray' (Self-Nonself Discrimination)
or 'Colour' (Integrity Model) by the Immune System.
Scand J Immunol 78:325-338 (2013).
- Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H,
Munthe LA, Dembic Z, Corthay A, and Bogen B:
How Do CD4(+) T Cells
Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
Front Immunol 5:174 (2014).
- Dembic Z:
Pharmaco-therapeutic challenges in cancer
biology with focus on the immune-system related risk factors.
Curr Pharm Des 20(42):6652-9 (2014).
- Gardar Sveinbjornsson, et al. ... Zlatko Dembic,... Ingileif Jonsdottir, & Kari Stefansson.
HLA class II sequence variants influence tuberculosis risk in populations of European ancestry
Nature Genetics 48, 318-322 (2016)
Some interesting sites
Molecular Genetics - Immunogenetics group
of Immunology home
and issues pages
Society for Immunology